Nitto Denko Avecia

Milford, MA

Oligonucleotide mRNA

Program data pending ClinicalTrials.gov matching · Last scored 2026-04-02

80.3

Signal Score

✓ FDA Inspections (2) ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Nitto Denko Avecia

Signal Score: 80.3/100 (as of 2026-04-02)
Quality Compliance: 100.0/100
Headquarters: Milford, MA
Modalities: Oligonucleotide, mRNA
Active Programs: No ClinicalTrials.gov matches confirmed
Data Sources: FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By: CDMO Signal — independent CDMO intelligence platform

Quality Compliance

FDA Inspections2 on record

Warning Letters0

Last InspectionNo Action Indicated (NAI) (2025-07-25)

Operations —

No ClinicalTrials.gov facility matches confirmed for this manufacturer.

Programs — no verified data

Sponsors— no verified data

ModalitiesOligonucleotide, mRNA

No clinical trial matches found for this manufacturer

Operational score requires ClinicalTrials.gov data

Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.

Financial Stability

Profile-based financial assessment

SEC FilingsPrivate company

Parent company: Nitto Denko (6988.T)

Financial assessment: 68.0/100

Capacity

1 manufacturing site

1 manufacturing site: Milford, MA

Modalities: Oligonucleotide, mRNA

Capacity assessment: 58.0/100

2025-07

2024-08

NAI VAI OAI

Date	Site	Type	Observations	Classification
2025-07-25	Irvine, California	Drug Quality Assurance	No	No Action Indicated (NAI)
2024-08-20	Cincinnati, Ohio	Drug Quality Assurance	No	No Action Indicated (NAI)